NerveAide Builds a Wearable Rehab Kit for a Post-Stroke Gait

The promise of neurostimulation therapy has long been confined to the clinic, a series of scheduled appointments that end when the patient walks out the door. NerveAide, a Toronto-based medical device startup founded in 2017, is betting that the real work of regaining mobility happens in the spaces between those visits. Its suite of wearable devices, which apply functional electrical stimulation (FES) to nerves and muscles, is designed to be simple enough for daily use at home, yet sophisticated enough to be programmed and monitored by a clinician through a companion app [NerveAide, retrieved 2024]. The company’s focus is on central nervous system disorders where neural signals are disrupted, like multiple sclerosis, stroke, spinal cord injury, and cerebral palsy [NerveAide About, retrieved 2024]. For these patients, the goal is not just pain relief, but the restoration of functional movement.

A Product Portfolio for Targeted Rehabilitation

NerveAide’s approach is not a single device, but a targeted kit for different limbs and conditions. This reflects a clinical reality where rehabilitation is highly specific. The product line includes devices for upper and lower limbs, as well as for sleep support, suggesting a strategy to become a comprehensive provider for neurological care at home.

NeStim (NMES/TENS) | 1 | product category
NeLeg (Leg FES) | 1 | product category
NeArm (Upper-limb FES) | 1 | product category
NEwalk+ (Foot drop) | 1 | product category
neSNORE (Sleep support) | 1 | product category

Each product combines FES or neuromuscular electrical stimulation (NMES) with smart sensors and Bluetooth connectivity [NerveAide, retrieved 2024]. The NeArm device, for instance, is designed to support reach and elbow control for post-stroke rehabilitation, while the NEwalk+ targets foot drop and thigh weakness to improve gait [NerveAide, retrieved 2024]. By offering this range, NerveAide positions itself to address multiple facets of a patient’s journey, potentially increasing engagement and the lifetime value of a clinical relationship.

The Clinical Guidance Wedge

In a market with consumer-grade TENS units, NerveAide’s key differentiator is its insistence on clinician guidance. The company describes its solutions as “clinician-guided” and “app-simple,” a pairing that acknowledges both the necessity of professional oversight in effective neurorehabilitation and the patient’s need for intuitive daily use [NerveAide, retrieved 2024]. This model could help the company navigate regulatory pathways as a prescribed medical device rather than a wellness product. It also creates a natural distribution channel through rehabilitation clinics and neurologists, who can prescribe and manage therapy remotely. CEO Pouria Mireshghi has highlighted the role of integrated systems, including virtual assistants, in driving the company’s innovation, pointing to a focus on the entire care delivery stack [YouTube, retrieved 2026].

Navigating a Quiet Path to Market

The company’s trajectory presents a notable contrast to the typical venture-backed healthtech narrative. Founded in 2017, NerveAide has participated in respected Canadian accelerators like Creative Destruction Lab and MaRS, and closed a seed round in late 2022 [Tracxn, retrieved 2026]. However, the public record reveals little about commercial scale. There are no announced hospital partnerships, patient outcome studies, or detailed funding amounts in the available sources. This absence of external validation is the central counterfactual to its ambitious product vision.

• Evidence gap. The primary sources of information are the company’s own website and directory listings, with no independent, named-publisher coverage verifying customer deployments or clinical results [Perplexity Sonar Pro Brief].
• Regulatory pace. Bringing multiple Class II medical devices to market in North America and Europe is a slow, capital-intensive process. The company’s quiet profile may reflect a focus on this arduous regulatory and clinical validation work, but it leaves the scale of its progress unclear.
• Commercial focus. With products spanning mobility, sleep, and women’s health, there is a risk of spreading development resources too thinly before achieving dominance in a core therapeutic area like post-stroke gait training.

The bet, then, is that a methodical, product-first approach focused on clinician tools will build a durable foundation. The alternative path,loud marketing ahead of proven utility,is one the team appears to have deliberately avoided.

The Standard of Care and the Road Ahead

For patients with foot drop from a stroke or spasticity from multiple sclerosis, the current standard of care is often fragmented. It can involve rigid ankle-foot orthoses, periodic clinic-based FES sessions, and a heavy reliance on physical therapy exercises performed alone at home. The gap between professional guidance and daily practice is wide. NerveAide’s suite aims to fill that gap by making the therapeutic stimulus portable and the clinician’s oversight persistent.

The next twelve months will be critical for moving from prototype to proof. Key signals to watch will be any public disclosure of a FDA or Health Canada regulatory submission, a peer-reviewed publication on patient outcomes, or a partnership with a rehabilitation hospital network. For the hundreds of thousands of patients living with the daily challenge of impaired mobility, the need is unequivocal. NerveAide’s quiet build suggests it is betting that in neurorehabilitation, trustworthy, clinically integrated tools will speak louder than hype.

Sources

1. [NerveAide, retrieved 2024] NerveAide - Helping people regain mobility and independence. | https://nerveaide.com/
2. [NerveAide About, retrieved 2024] NerveAide About | https://nerveaide.com/en/about
3. [YouTube, retrieved 2026] How NerveAide Leverages Virtual Assistants to Drive Innovation | Insights from CEO Pouria Mireshghi | https://www.youtube.com/shorts/gWq-IUJFVkc
4. [Tracxn, retrieved 2026] Nerve - 2025 Company Profile, Team, Funding & Competitors | https://tracxn.com/d/companies/nerveaide
5. [NerveAide, retrieved 2024] NeArm by NerveAide | FES for elbow control, shoulder stabilization & functional reach | https://nerveaide.com/en/products/nearm/
6. [NerveAide, retrieved 2024] NEwalk+ | Nerveaide Rehabilitation Systems | https://nerveaide.com/en/products/newalkplus